Cargando…

Assessing Rates of Co-Resistance and Patient Outcomes in Multidrug-Resistant Pseudomonas aeruginosa

Multidrug-resistant (MDR) Pseudomonas aeruginosa infections are associated with poor patient outcomes due to complex co-resistance patterns. We described common co-resistance patterns, clinical characteristics, and associated outcomes in patients admitted with an MDR P. aeruginosa. This national, mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Appaneal, Haley J., Caffrey, Aisling R., Lopes, Vrishali, Piehl, Emily C., Puzniak, Laura A., LaPlante, Kerry L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603501/ https://www.ncbi.nlm.nih.gov/pubmed/36005836 http://dx.doi.org/10.1128/spectrum.02336-22

Ejemplares similares

The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections
por: Caffrey, Aisling R., et al.
Publicado: (2022)

2291. Evaluation of Multidrug-Resistant Pseudomonas aeruginosa Isolates in Patients Receiving Ceftolozane/tazobactam
por: Bodo, Emily C, et al.
Publicado: (2019)

846. Trends in Acinetobacter baumanii Antibiotic Resistance Rates
por: Caffrey, Aisling, et al.
Publicado: (2020)

847. Trends in Stenotrophomonas maltophilia Antibiotic Resistance Rates
por: Caffrey, Aisling, et al.
Publicado: (2020)

1628. Treatment Heterogeneity in Pseudomonas aeruginosa Pneumonia
por: Caffrey, Aisling, et al.
Publicado: (2020)

Treatment Heterogeneity in Pseudomonas aeruginosa Pneumonia
por: Caffrey, Aisling R., et al.
Publicado: (2022)

1610. Epidemiology and Treatment Heterogeneity in Acinetobacter baumanii Infections
por: Caffrey, Aisling, et al.
Publicado: (2020)

1585. Stenotrophomonas maltophilia Infections and Approaches to Treatment
por: Caffrey, Aisling, et al.
Publicado: (2020)

2049. Trends in Antibiotic Use and Antibiotic Resistance among Veterans Affairs Community Living Centers from 2011 to 2017
por: Appaneal, Haley, et al.
Publicado: (2019)

Decreasing Antibiotic Resistance Trends Nationally in Gram-Negative Bacteria Across United States Veterans Affairs Medical Centers, 2011–2020
por: Liao, J. Xin, et al.
Publicado: (2023)

Antibiotic Prescribing in Outpatient Settings: Rural Patients Are More Likely to Receive Fluoroquinolones and Longer Antibiotic Courses
por: Appaneal, Haley J., et al.
Publicado: (2023)

1238. A National Comparison of Antibiograms Between Veterans Affairs Long-Term Care Facilities and Affiliated Hospitals
por: Tolg, Maria-Stephanie, et al.
Publicado: (2018)

2012. Trends in Microbiological Culture Collection Across Veterans Affairs Medical Centers and Community Living Centers, 2010 to 2017
por: Appaneal, Haley, et al.
Publicado: (2019)

470. Concomitant Antibiotic Use and Death Among a National Cohort of Veterans With Clostridium difficile Infection (CDI)
por: Appaneal, Haley, et al.
Publicado: (2018)

699. Relationship Between Klebsiella pneumoniae Antimicrobial Resistance and Biofilm Formation
por: Cusumano, Jaclyn, et al.
Publicado: (2018)

Poor clinical outcomes associated with suboptimal antibiotic treatment among older long-term care facility residents with urinary tract infection: a retrospective cohort study
por: Appaneal, Haley J., et al.
Publicado: (2021)

Post-Discharge Antibiotic Therapy in Patients with Acute Bacterial Skin and Skin Structure Infections
por: Caffrey, Aisling, et al.
Publicado: (2017)

Impact of Vancomycin-Associated Acute Kidney Injury on Patient Outcomes in MRSA Bacteremia
por: Luther, Megan, et al.
Publicado: (2017)

1067. Comparative Effectiveness of Nafcillin or Oxacillin, Cefazolin, and Piperacillin/Tazobactam in Methicillin-Sensitive Staphylococcus aureus Bacteremia
por: Beganovic, Maya, et al.
Publicado: (2018)

Heterogeneity in the treatment of bloodstream infections identified from antibiotic exposure mapping
por: Caffrey, Aisling R., et al.
Publicado: (2019)

264. Anti-platelet Therapy Significantly Reduces Inpatient Mortality in Patients with Staphylococcus aureus Bacteremia
por: Caffrey, Aisling, et al.
Publicado: (2020)

Predictors of 30-day All-cause Mortality in Veterans with First Recurrence of Clostridium difficile Infection (CDI)
por: Morrill, Haley, et al.
Publicado: (2017)

192 Vancomycin Dosing in Obese and Morbidly Obese Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia
por: Morrill, Haley, et al.
Publicado: (2014)

Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis
por: Raman, Gowri, et al.
Publicado: (2018)

Erratum to: Epidemiology of Pneumococcal Disease in a National Cohort of Older Adults
por: Morrill, Haley J., et al.
Publicado: (2014)

Epidemiology of Pneumococcal Disease in a National Cohort of Older Adults
por: Morrill, Haley J., et al.
Publicado: (2014)

Impact of a Prospective Audit and Feedback Antimicrobial Stewardship Program at a Veterans Affairs Medical Center: A Six-Point Assessment
por: Morrill, Haley J., et al.
Publicado: (2016)

The prevalence of Pseudomonas aeruginosa and multidrug resistant Pseudomonas aeruginosa in healthy captive ophidian
por: Sala, Andrea, et al.
Publicado: (2019)

Effect of methylglyoxal on multidrug-resistant Pseudomonas aeruginosa
por: Hayashi, Katsuhiko, et al.
Publicado: (2014)

Multidrug resistant Pseudomonas aeruginosa in Estonian hospitals
por: Telling, Kaidi, et al.
Publicado: (2018)

A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Hart, Delaney E, et al.
Publicado: (2021)

Emergence and Spread of Epidemic Multidrug-Resistant Pseudomonas aeruginosa
por: Miyoshi-Akiyama, Tohru, et al.
Publicado: (2017)

Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
por: Kunz Coyne, Ashlan J., et al.
Publicado: (2022)

1323. Substantial Doses of Daptomycin and Rifampin Eradicate S. epidermidis Biofilm in an In Vitro Pharmacodynamic (IVPD) Model
por: Piehl, Emily C, et al.
Publicado: (2020)

1630. What is Treatment Time Zero Among Hospitalized Patients with Bacteremia?
por: Caffrey, Aisling, et al.
Publicado: (2020)

2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients with Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PA) Infections
por: Hart, Delaney E, et al.
Publicado: (2019)

Polimixin B use in treatment of multidrug-resistant Pseudomonas aeruginosa infection
por: Gouveia, LS, et al.
Publicado: (2003)

Genotypic Characterization of Multidrug-Resistant Pseudomonas aeruginosa Using Whole-Genome Sequencing
por: Abdalhamid, Baha, et al.
Publicado: (2021)

Carbapenem Susceptibility and Multidrug-Resistance in Pseudomonas aeruginosa Isolates in Egypt
por: Hashem, Hany, et al.
Publicado: (2016)

S33.1 Multidrug-resistant Acinetobacter baumanii and Pseudomonas aeruginosa
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_6mpisk7ef32i53jp789phapsc2